2025-12-21 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the data provided.

**1) Return Rate Comparison:**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions to consumers.
*   **HIMS Cumulative Return:** 129.58%
*   **VOO (S&P 500) Cumulative Return:** 74.84%
*   **Divergence:** 68.3 (Relative Divergence: 37.9)

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) in cumulative return.  The current divergence between HIMS and VOO is 68.3, placing it at the 37.9th percentile of its historical divergence range. This suggests that while HIMS has performed well, its relative outperformance is currently not at its peak compared to past fluctuations.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD  | Alpha | Beta  | Cap(B) |
|------------|--------|------|-------|-------|--------|
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0   | 1.5    |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0  | 1.5    |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1  | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0  | 5.5    |
| 2023-2025  | 134.0% | 80.8% | 69.0%  | 0.1   | 8.1    |

**Analysis:**
*   **CAGR:**  The CAGR shows a volatile performance history, with significant negative returns in earlier periods and strong positive returns in the most recent periods.
*   **MDD:**  The Maximum Drawdown (MDD) is consistently high, indicating significant risk and potential for large losses.
*   **Alpha:**  Alpha values have fluctuated significantly, mirroring the company's performance. Recent years show a high positive Alpha, suggesting HIMS generated excess return compared to its benchmark.
*   **Beta:**  Beta is consistently near zero.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 35.56
*   **Last Market Data:** Price: 35.56, Previous Close: 34.77, Change: 2.27
*   **5-day SMA:** 35.68
*   **20-day SMA:** 37.36
*   **60-day SMA:** 44.56

**Analysis:** The current closing price is below both the 20-day and 60-day Simple Moving Averages, suggesting a short-term downtrend.  The 5-day SMA is very close to the current price, indicating recent stabilization or a slight uptrend. The recent price increase of 2.27 suggests a short-term rebound.

**3) Technical Indicators and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 44.60
*   **PPO:** 0.02
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 1.1 (+) (Short-term increase)
*   **Expected Return (%):** 24.2% (Expected excess return compared to S&P 500 if invested long-term)

**Analysis:**

*   The MRI of 0.7 suggests a medium level of investment risk.
*   The RSI of 44.60 indicates that the stock is neither overbought nor oversold.
*   The PPO value of 0.02 suggests the short-term moving average is negligibly above the long-term moving average.
*   The hybrid signal recommends buying the stock.
*   The 20-day relative divergence change is positive, suggesting a recent upward trend.
*   The expected return of 24.2% is quite high, indicating potential for significant long-term gains compared to the S&P 500.

**4) Recent News & Significant Events:**

*   **Negative:**
    *   "$HIMS stock fell 5% this week." (Quiver Quantitative)
    *   "Michael Chi Sells 13,750 Shares of Hims & Hers Health (NYSE:HIMS) Stock" (MarketBeat)
*   **Mixed/Neutral:**
    *   "Hims & Hers Health (HIMS): Taking Stock of Valuation After a Sharp 90‑Day Pullback" (Yahoo Finance) - This suggests a recent price decline followed by potential undervaluation.
    *   "Hims & Hers Scales Technology-Driven Care as Profitability Evolves" (Zacks) - Highlights growth in business model.
*   **Positive:**
    *   "Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization" (Hims Investor Relations) - This typically indicates the company believes its stock is undervalued and aims to boost share price.
    *   "Hims & Hers: The Market's Panic Is Irrational (NYSE:HIMS)" (Seeking Alpha) - Suggests the recent sell-off might be an overreaction.

**Analysis:** The news is mixed.  The share repurchase program and articles suggesting the market is overreacting are positive signals.  However, the report of a 5% stock decline and insider selling are negative. The articles discussing valuation adjustments indicate uncertainty.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.93 (~Hold)
*   **Number of Opinions:** 12
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00
*   **Recent Rating Changes:** (No specific changes listed, but implied to be neutral)

**Analysis:**  The analyst consensus is "Hold," indicating a neutral outlook on the stock. The average target price of $44.67 suggests a potential upside from the current price of $35.56. However, the wide range between the high and low target prices reflects uncertainty among analysts.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-03 | 0.07 | 0.60 B$   |
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2025-11-03 | 0.35 | 0.40 B$   |

**Analysis:**
* The numbers are inconsistent. The dates are mixed up, and duplicate data appear. But based on recent trend, EPS seems to be in the range of 0.07 ~ 0.22, and Revenue seems to be in the range of 0.54 B$ ~ 0.60 B$.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30 | $0.60B     | 73.80%        |
| 2025-06-30 | $0.54B     | 76.39%        |
| 2025-03-31 | $0.59B     | 73.50%        |
| 2024-12-31 | $0.48B     | 76.81%        |
| 2024-09-30 | $0.40B     | 79.16%        |

**Analysis:** Revenue has been consistently increasing over the past five quarters. Profit margins are high (above 70%) but have shown some fluctuation, trending slightly downwards in recent quarters.

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30 | $0.58B    | 2.72% |
| 2025-06-30 | $0.56B    | 7.55% |
| 2025-03-31 | $0.55B    | 9.01% |
| 2024-12-31 | $0.48B    | 5.46% |
| 2024-09-30 | $0.44B    | 17.18% |

**Analysis:** Equity has been steadily increasing. ROE is highly variable, suggesting the business is not stable.

**7) Comprehensive Analysis (Summary):**

Hims & Hers Health Inc. (HIMS) presents a mixed investment picture:

*   **Positive Factors:**
    *   Strong outperformance compared to the S&P 500 in recent years.
    *   High expected return (24.2%).
    *   Revenue growth and high profit margins.
    *   Recent share repurchase program.
    *   Articles suggesting potential undervaluation.
    *   Hybrid signal recommends a buy
*   **Negative Factors:**
    *   High Maximum Drawdown historically, indicating volatility.
    *   Recent stock price decline and insider selling.
    *   Slowing growth momentum
    *   Analyst consensus is "Hold," and target prices vary widely.
    *   Recent numbers do not show profits or high ROE.
    *   Recent numbers do not show good trend.

**Conclusion:**

HIMS appears to be a growth stock with high potential rewards but also significant risks. The company has demonstrated the ability to outperform the market, and its revenue is growing. However, the high volatility, recent negative news, inconsistent financial data, and neutral analyst sentiment suggest caution. Investors should carefully consider their risk tolerance and conduct further due diligence before investing. The current stock price dip *may* present an opportunity, but the company's path to profitability and consistent growth remains uncertain.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.